MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2

Medical Oncology

Volumn 31, Issue 6, 2014, Pages

  Sun, ZhiFeng ^a   Zhang, Zhang ^b   Liu, Zidong ^a   Qiu, Bo ^b   Liu, Kan ^a   Dong, Guanglong ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Colorectal cancer; Metastasis; miR 335; Prognosis; ZEB2

Indexed keywords

MICRORNA; MICRORNA 335; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; HOMEODOMAIN PROTEIN; MIRN335 MICRORNA, HUMAN; REPRESSOR PROTEIN; ZEB2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERACTIONS WITH RNA; LIVER METASTASIS; LUCIFERASE ASSAY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR INVASION; TUMOR SUPPRESSOR GENE; VERY ELDERLY; ZEB2 GENE; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL TUMOR; DOWN REGULATION; DRUG SCREENING; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROGNOSIS; REPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84901559958     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0982-8     Document Type: Article

References (33)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719): 1030-47. doi:10.1016/S0140-6736(10) 60353-4.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
4. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775-89. doi:10.1038/nrd3179.
5. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69. doi:10.1038/ nrc1840.
6. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515-24. doi:10.1016/j.cell.2012.04.005.
7. Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, et al. Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat. 2012;33(12):1665-75. doi:10.1002/humu.22159.
8. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128-36. doi:10.1038/sj.onc.1210856. (Pubitemid 351485639)
9. Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS ONE. 2012;7(7):e40037. doi:10.1371/journal.pone. 0040037.
10. Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, et al. MicroRNA- 335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31(11): 1398-407. doi:10.1038/onc.2011.340.
11. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 2013;25(1):46-54. doi:10.3978/j. issn.1000-9604.2012.11.04.
12. Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q, et al. miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141(3):437-42. doi:10.1309/ AJCPLYTZGB54ISZC.
13. Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. Micro- RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2014;. doi:10.3109/09513590.2013. 871525.
14. Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, et al. miR-335 inhibits small cell lung cancer bone metastases via IGFIR and RANKL pathways. Mol Cancer Res. 2014;12(1):101-10. doi:10.1158/1541-7786.MCR-13-0136.
15. Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun. 2013;430(2):529-34. doi:10.1016/j.bbrc.2012.12.001.
16. Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res POR. 2013;19(3):529-37. doi:10.1007/ s12253-013-9613-5.
17. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009;69(19):7495-8. doi:10.1158/0008-5472.CAN-09-2111.
18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. doi:10.1038/nrc1997. (Pubitemid 44629897)
19. Wang Y, Zhao W, Fu Q. miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;384(1-2):105-11. doi:10.1007/s11010-013- 1786-4.
20. Wang H, Li M, Zhang R, Wang Y, Zang W, Ma Y, et al. Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour Biol J Int Soc Oncodevelop Biol Med. 2013;34(5):3101-9. doi:10.1007/s13277-013-0878-9.
21. Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 2013;30(2):701-6. doi:10.3892/or. 2013.2482.
22. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25(3):226-31. doi:10.1101/gad.1974211.
23. Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53- dependent stress response. Cancer Res. 2010;70(17):6925-33. doi:10.1158/0008-5472.CAN-10-0141.
24. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, et al. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006;25(36):4975-85. doi:10. 1038/sj.onc.1209511.
25. Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 2012;19(Suppl 3):S656-64. doi:10. 1245/s10434-012-2217-6.
26. Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu BC, et al. Epi-thelial- mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. Oral Oncol. 2013; 49(1):34-41. doi:10.1016/j.oraloncology.2012.07.012.
27. Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE. 2012;7(6): e38842. doi:10.1371/journal.pone.0038842.
28. Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB, Hou JH, et al. Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma. PLoS ONE. 2012;7(2):e32838. doi:10.1371/journal. pone.0032838.
29. Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1 + ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol. 2011;122(1): 149-54. doi:10.1016/j.ygyno.2011.03. 026.
30. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011;300(1):66-78. doi:10.1016/j.canlet.2010.09.007.
31. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-28. doi:10.1038/nrc2131. (Pubitemid 46809165)
32. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267-78. (Pubitemid 32607360)
33. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005;33(20):6566-78. doi:10.1093/nar/gki965. (Pubitemid 41806421)